Adipo Therapeutics develops Notch-inhibiting nanoparticles that convert white adipose tissue into metabolically active brown fat, enhancing energy expenditure without requiring calorie restriction. This approach addresses the challenge of sustained weight loss and metabolic health in the face of rising obesity rates.
Funding
$8.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Obesity rates are rising, and traditional weight loss methods relying on calorie restriction often fail due to the body's metabolic adaptation, making sustained weight loss difficult. Calorie restriction can also deprive the body of vital nutrients needed to maintain muscle mass and healthy body composition.
Solution
Adipo Therapeutics is developing a therapeutic approach to combat obesity and related metabolic diseases by increasing energy expenditure. Their investigational product utilizes Notch-inhibiting nanoparticles to convert white adipose tissue, which stores energy, into metabolically active brown fat, which burns energy. This conversion aims to promote weight loss and improve metabolic health without requiring calorie restriction. Preclinical animal studies have demonstrated weight loss and improved blood glucose and lipid control without changes in calorie intake.
Target Audience
The primary target audience includes individuals struggling with obesity and related metabolic disorders, as well as healthcare providers seeking novel therapeutic interventions.
Features
- Utilizes Notch-inhibiting nanoparticles to target white adipose tissue.
- Promotes the conversion of white fat to brown fat, increasing energy expenditure.
- Designed to improve blood glucose and lipid control.
- Aims to address metabolic adaptation that hinders sustained weight loss from calorie restriction.